LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
24h
Actual
Mínimo
47.22
Máximo
47.98
Recomendaciones | Comprar |
---|---|
Estimación a 12 meses | +40.08 upside |
Próximas Ganancias | 19 feb 2025 |
---|
By Acuity
50%
50%
162 / 392 Clasificación en Healthcare
By Trading Central
Confianza
Very Strong Bearish Evidence
47.25 / 52.52 Soporte y Resistencia
El rendimiento pasado no es un indicador fiable de resultados futuros.
8 dic 2023, 20:56 UTC
Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment
DJ
Leer
26 sept 2024, 16:08 UTC
Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com
DJ
Leer
26 sept 2024, 14:20 UTC
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD
DJ
Leer
11 abr 2024, 14:46 UTC
Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com
DJ
Leer
8 dic 2023, 18:45 UTC
FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update
DJ
Leer
8 dic 2023, 16:45 UTC
FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update
DJ
Leer
8 dic 2023, 16:21 UTC
FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- WSJ
DJ
Leer
Cambio de precio
By TipRanks
Estimación a 12 meses
Media 67.07 USD 40.08%
Máximo 100 USD
Mínimo 30 USD
De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CRISPR Therapeutics AG Dist en los últimos 3 meses.
By TipRanks
Comprar
17 ratings
9
Comprar
6
Mantener
2
Vender
De acuerdo con 17 analistas que ofrecen calificaciones bursátiles a para CRISPR Therapeutics AG Dist en los últimos 3 meses.
By Trading Central
Corto Plazo
Very Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Medio plazo
Bearish Evidence
Recent bearish events outweigh bullish events.
Largo Plazo
Weak Bearish Evidence
All events are bearish.
By Acuity
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
$